home / stock / vera / vera news

VERA News and Press, Vera Therapeutics Inc. From 02/08/22

Stock Information
Company Name: Vera Therapeutics Inc.
Stock Symbol: VERA
Market: NASDAQ
Website: veratx.com
Menu
VERA VERA Quote VERA Short VERA News VERA Articles VERA Message Board
Get VERA Alerts

News, Short Squeeze, Breakout and More Instantly...
VERA - Haemonetics, Second Sight top healthcare gainers; Pulse, Karyopharm lead losers

Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...
VERA - Vera Therapeutics announces public offering of 4M class A shares

Vera Therapeutics (NASDAQ:VERA) commenced a public offering to issue and sell 4M class A shares. VERA expects to grant the underwriters a 30-day option to purchase up to an additional 600K class A shares. For further details see: Vera Therapeutics announces public offering of 4M class A...

VERA - Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced ...

VERA - Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical...
VERA - Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD,...

VERA - Vera Therapeutics gives back gains from Friday's Pfizer deal; closes down 18%

Vera (NASDAQ:VERA) has more than given back gains it made on Friday following the acquisition of a monoclonal antibody candidate from Pfizer (NYSE:PFE), closing down 18%. The deal with Pfizer is for MAU868, a first-in-class monoclonal antibody to treat BK virus, the leading cause of kidn...

VERA - Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of transplant loss and transplant-associated morbidity BRISBANE, Calif., Dec....
VERA - Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball...

VERA - DWAC, EFOI and AVCT among mid-day movers

Gainers: Insignia Systems (NASDAQ:ISIG) +106%. Energy Focus (NASDAQ:EFOI) +65%. Virpax (NASDAQ:VRPX) +26%. Aziyo (NASDAQ:AZYO) +26%. Digital World Acquisition (NASDAQ:DWACU) +20%. Digital World Acquisition (NASDAQ:DWAC) +20%. RLX Technology (NYSE:RLX) +20%. The Lovesac (NASDAQ:LOVE) +19%. Pho...

VERA - Inotiv, Theravance Biopharma leads healthcare gainers; Radius Health, Ensysce Biosciences among major losers

Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
Previous 10 Next 10